Luseogliflozin for the treatment of type 2 diabetes

Bibliography

• International Diabetes Federation. IDF Diabetes Atlas. 6th edition. Available from: http://www.idf.org/diabetesatlas/ [Last accessed 29 January 2014]
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson M, Barzilay J, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19:536-57
   PubMed Web of Science ®Google Scholar
• Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-31
   PubMed Web of Science ®Google Scholar
• Ahren B. DPP-4 inhibition and islet function. J Diabetes Investig 2012;3:3-10
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
   PubMed Web of Science ®Google Scholar
• Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636-43
   PubMed Web of Science ®Google Scholar
• Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2:e001007
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011;164:181-91
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93
   PubMed Web of Science ®Google Scholar
• Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 2013;139:51-9
   PubMed Web of Science ®Google Scholar
• Acquisition of manufacturing and marketing approval in Japan for SGLT2 inhibitor Lusefi® tablets 2.5 mg and Lusefi® tablets 5 mg [media release]. Taisho Pharmaceutical Holdings Co., Ltd., Tokyo; 2014. Available from: http://www.taisho-holdings.co.jp/en/release/2014/2014032401-e.pdf [Last accessed 8 August 2014]
   Google Scholar
• Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53:3247-61
   PubMed Web of Science ®Google Scholar
• Lusefi® tablets 2.5/5 mg package insert. Tokyo: Taisho Pharmaceutical Co., Ltd., 2014. Available from: http://www.info.pmda.go.jp/go/pack/3969020F1020_1_01/ [Last accessed 12 August 2014]; In Japanese
   Google Scholar
• Chino Y, Hasegawa M, Hachiuma K, et al. Pharmacokinetics and prediction of drug-drug interaction of TS-071 a selective SGLT2 inhibitor. 26th JSSX Annual Meeting; 16 – 18 November 2011; Hiroshima, Japan;. Poster Session 2-P2-28
   Google Scholar
• Miyata A, Hasegawa M, Mori H, et al. Characterization of the human enzymes involved in the metabolism of luseogliflozin (TS-071), a selective SGLT2 inhibitor. 28th JSSX Annual Meeting; 9 – 11 October 2013; Tokyo, Japan; Poster Session 2-G-P-17
   Google Scholar
• The pharmaceutical interview form, supplemental to the package insert for Lusefi® tablets 2.5/5 mg. Tokyo: Taisho Pharmaceutical Co., Ltd., 2014. Available from: http://www.info.pmda.go.jp/go/pack/3969020F1020_1_01/ [Last accessed 12 August 2014]; In Japanese
   Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 2014;31:345-61
   PubMed Web of Science ®Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co-transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes (EASD) Annual Meeting; 12 – 16 September 2011; Lisbon, Portugal; Poster 846
   Google Scholar
• Sasaki M, Seino Y, Samukawa Y, et al. Effects of gender and age on the pharmacokinetics and pharmacodynamics of luseogliflozin (TS-071), a selective SGLT2 inhibitor. 72nd Scientific Sessions of the American Diabetes Association; 8 – 12 June 2012; Philadelphia, PA, USA; Poster 1069-P
   Google Scholar
• Haneda M, Seino Y, Sasaki T, et al. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment. 48th European Association for the Study of Diabetes (EASD) Annual Meeting; 1 – 5 October 2012; Berlin, Germany; Poster 741
   Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245-55
   PubMed Web of Science ®Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. Luseogliflozin, a selective SGLT2 inhibitor, improves glycemic control as monotherapy in Japanese patients with T2DM. International Diabetes Federation 2013 World Diabetes Congress; 2 – 6 December 2013; Melbourne, Australia; Poster P-1472
   Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. Consistent efficacy of add-on combination of luseogliflozin with conventional oral antidiabetic drugs in Japanese patients with T2DM. International Diabetes Federation 2013 World Diabetes Congress; 2 – 6 December 2013; Melbourne, Australia; Poster P-1471
   Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
   PubMed Web of Science ®Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
   PubMed Web of Science ®Google Scholar
• Launch of Suglat® tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes- first SGLT2 Inhibitor in Japan, providing new options in the treatment of type 2 diabetes [media release]. Astellas Pharma Inc., Tokyo. Available from: http://www.astellas.com/en/corporate/news/detail/launch-of-suglat-tablets-a-sel.html [Last accessed 12 August 2014]
   Google Scholar
• Forxiga® receives regulatory approval in Japan for the treatment of type 2 diabetes [media release]. Ono Pharmaceutical Co., Ltd., Osaka, AstraZeneca, London. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20140324--forxiga-japan-approval [Last accessed 12 August 2014]
   Google Scholar
• Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs 2014;74:939-44
   PubMed Web of Science ®Google Scholar
• Marketing and manufacturing approval in Japan received for Canaglu® tablets 100 mg [media release]. Mitsubishi Tanabe Pharma Corporation, Osaka; Daiichi Sankyo Co., Ltd., Tokyo. Available from: http://www.mt-pharma.co.jp/e/release/nr/2014/pdf/e_MTPC140704.pdf [Last accessed 25 August 2014]
   Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin 2014;30:1231-44
   PubMed Web of Science ®Google Scholar